We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Impax

News List

FDA Announces Alert of Amneal, Impax Epinephrine Auto-Injector Malfunctions americanpharmaceuticalreview
June 11, 2020
FDA is alerting patients, caregivers and health care professionals to immediately inspect certain lots of Amneal and Impax epinephrine auto-injector 0.3 mg to ensure the yellow “stop collar” in the device is present.
Impax to sell Taiwan, China manufacturing facility to Bora Pharmaceuticals biospectrumasia
December 25, 2017
As a result of the sale, Impax expects to record a pre-tax impairment charge of approximately $70.0 to $80.0 million in the fourth quarter of this year
Amneal Pharmaceuticals in agreement with Impax Laboratories expressbpd
October 19, 2017
Amneal Pharmaceuticals and Impax Laboratories have entered into a definitive business combination in an all-stock transaction.
FDA approves Impax's AB rated generic Concerta Extended-Release Tablets CII cphi-online
July 19, 2017
Company expects to launch by the end of the year.
Impax Announces FDA Approval of AB Rated Generic Concerta Extended-Release Tablets CII americanpharmaceuticalreview
July 18, 2017
Impax announced it has received an AB therapeutic equivalent rating and final U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug Application for a generic version of Concerta (methylphenidate hydrochloride) Extended-Release table